Skip to main content
Daehan Nupharm Co.,Ltd. logo

Daehan Nupharm Co.,Ltd. — Investor Relations & Filings

Ticker · 054670 ISIN · KR7054670005 LEI · 988400PSHJB5UWD6MA19 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 184 across all filing types
Latest filing 2024-04-30 Major Shareholding Noti…
Country KR South Korea
Listing KO 054670

About Daehan Nupharm Co.,Ltd.

https://www.dhnp.co.kr

Daehan Nupharm Co., Ltd. is a pharmaceutical company that develops, manufactures, and markets a wide range of health products. Its business is structured around four key segments: human pharmaceuticals, providing effective and safe therapeutics; animal health, offering products for both livestock and companion animals; biopharmaceuticals, focusing on the development of next-generation treatments such as cell therapy; and health functional foods. The company prioritizes innovation and quality through its dedicated research and development centers, aiming to advance health outcomes with scientifically-backed solutions.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. It details changes in share ownership, including special relationships, share pledges, and specific transaction history (time-outside trading). This type of filing is a regulatory requirement for significant shareholders to disclose their holdings and changes in control, which falls under the 'Major Shareholding Notification' category.
2024-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the share ownership changes of a specific director (Lee Wonsuk) of the company 'Daehan New Pharm'. This type of filing is a standard regulatory disclosure for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2024-04-24 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (정기주주총회결과). It details the approval of financial statements, dividend resolutions, and the election of directors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements, as it reports the outcome of shareholder votes.
2024-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/proper) and key financial data (assets, liabilities, revenue, profit) for the fiscal year. While it contains financial data, it is a standard regulatory disclosure announcement regarding the receipt and submission of the audit report, rather than the full annual report document itself. According to the 'Menu vs Meal' rule, this is a notification of the report's availability/submission, fitting the definition of a Report Publication Announcement (RPA). FY 2023
2024-03-08 Korean
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 40th fiscal year (2023) of Daehan New Pharm Co., Ltd. It contains comprehensive financial statements, management discussion and analysis, governance information, and operational details. This document is the standard Korean regulatory filing equivalent to a 10-K in the US market. FY 2023
2024-03-08 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) which includes a 'Correction Report' (정정신고) regarding financial statements and electronic voting procedures. This document serves as the official proxy statement and meeting notice sent to shareholders to inform them of the upcoming AGM, agenda items, and voting procedures. In the context of the provided filing categories, this is classified as a Proxy Solicitation & Information Statement (PSI).
2024-03-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.